FibroBiologics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-16.
FibroBiologics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 16, 2025. The filing reports $1.73M sold. Its industry group is Pharmaceuticals. It names Pete O'Heeron (Chairman, Founder and Chief Executive Officer), Stacy Coen (Director), Robert Hoffman (Director) (SEC Form D, December 16, 2025).
Sell to companies like FibroBiologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns FibroBiologics, Inc.
Free to see. No signup.
More on the people and the money behind FibroBiologics, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in Texas, filed within 90 days of this one, largest first.
Get an email when FibroBiologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when FibroBiologics, Inc. raises, hires or launches. No email unless you switch it on.
Watch FibroBiologics, Inc. →Get the full cited report on FibroBiologics, Inc.
What the filing shows about FibroBiologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for FibroBiologics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $1.73M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The issuer intends to use the net proceeds from this offering for working capital and general corporate purposes.
On the filing as: Executive Officer, Director.
Pete O'Heeron is named as Chairman, Founder and Chief Executive Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
Stacy Coen is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
Robert Hoffman is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
Matthew Link is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
Victoria Niklas is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
Richard Cilento is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
On the filing as: Executive Officer.
Jason Davis is named as Chief Financial Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 December 2025, one of 7 people that filing names.
7 people named on the filing — 2 holding an executive role and 5 as directors only.
Named as of the 2025-12-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about FibroBiologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FibroBiologics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist FibroBiologics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind FibroBiologics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for FibroBiologics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Houston
https://mentionfox.com/funding/fibrobiologics-inc-form-d-25000001